Atopic Dermatitis

Below is a list of our atopic dermatitis studies that are currently enrolling.

 

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age with Moderate-to-Severe Atopic Dermatitis

• Population: Patients aged 6 months to less than 18 years
• Study Condition: Moderate-to-Severe Atopic Dermatitis (AD)
• Study Design: This is a randomized, double-blind, placebo-controlled, Phase 3 study to assess the efficacy, safety and pharmacokinetics of lebrikizumab in participants 6 months to <18 years of age with moderate-to-severe AD. Subjects will be randomized in a 2:1 ratio to receive either lebrikizumab or placebo. Subjects will attend 12 clinic visits for up to 30 weeks. Participants who complete this trial may be given the option to enroll into a long-term extension study where lebrikizumab will be provided.
• Compensation for time and travel may be provided 

A Study of Upadacitinib in Adult Participants with Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (SWITCH-UP)

• Population: Adult subjects ≥ 18 years of age and < 64
• Study Condition: Moderate to severe atopic dermatitis (AD) and inadequate response to dupilumab after at least 6 months of current use
• Study Design: This is a global, Phase 3b/4, randomized, open-label, efficacy assessor-blinded, multi-center study that will evaluate upadacitinib compared to dupilumab in adult subjects with moderate to severe AD and inadequate response to dupilumab after at least 6 months of current use. The study consists of a 35-day Screening Period; an 8-week randomized, open-label, efficacy assessor blinded treatment period for all participants (Period 1); a 24-week open-label, efficacy assessor-blinded extension period for all participants who finish Period 1 (Period 2) (total duration of Period 1 and Period 2 is 32 weeks); and a 30-day Follow-up visit.
• Compensation may be provided for study participation

  

A Study of Upadacitinib Compared to Dupilumab in Pediatric Subjects with Moderate-to-Severe Atopic Dermatitis (START UP)

• Population: Pediatric subjects 6 years of age and < 12
• Study Condition: Moderate to severe atopic dermatitis (AD) for at least 6 months.
• Study Design: This is a Phase 3, open-label, efficacy-assessor-blinded Study, comparing the safety and efficacy of upadacitinib to dupilumab in children from 6 to less than 12 years of age with moderate to severe AD who are candidates for systemic therapy for AD. The study consists of a 35-day Screening Period; a 16-week randomized, open-label, efficacy assessor blinded treatment period for all subjects; an open-label period lasting up to week 52 for subjects in dupilumab arm; an open-label period lasting up to week 160 for subjects assigned to upadacitinib; and a 30-day follow up visit/call after the last dose is administered for upadacitinib or dupilumab.
• Compensation may be provided for participation.

 

Please contact Courtney Rowley for more information regarding ongoing atopic dermatitis studies. 

Email: rowle@musc.edu

Phone: (843) 792-9784